269 related articles for article (PubMed ID: 27500733)
1. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
[TBL] [Abstract][Full Text] [Related]
2. Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.
Yu RZ; Graham MJ; Post N; Riney S; Zanardi T; Hall S; Burkey J; Shemesh CS; Prakash TP; Seth PP; Swayze EE; Geary RS; Wang Y; Henry S
Mol Ther Nucleic Acids; 2016 May; 5(5):e317. PubMed ID: 27138177
[TBL] [Abstract][Full Text] [Related]
3. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc
Wang Y; Yu RZ; Henry S; Geary RS
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):475-485. PubMed ID: 31144994
[No Abstract] [Full Text] [Related]
5. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
[TBL] [Abstract][Full Text] [Related]
6. Safety and Tolerability of GalNAc
Baker BF; Xia S; Partridge W; Engelhardt JA; Tsimikas S; Crooke ST; Bhanot S; Geary RS
Nucleic Acid Ther; 2024 Feb; 34(1):18-25. PubMed ID: 38227794
[TBL] [Abstract][Full Text] [Related]
7. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
[TBL] [Abstract][Full Text] [Related]
8. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes.
Tanowitz M; Hettrick L; Revenko A; Kinberger GA; Prakash TP; Seth PP
Nucleic Acids Res; 2017 Dec; 45(21):12388-12400. PubMed ID: 29069408
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor.
Schmidt K; Prakash TP; Donner AJ; Kinberger GA; Gaus HJ; Low A; Østergaard ME; Bell M; Swayze EE; Seth PP
Nucleic Acids Res; 2017 Mar; 45(5):2294-2306. PubMed ID: 28158620
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.
Yu RZ; Zhang H; Geary RS; Graham M; Masarjian L; Lemonidis K; Crooke R; Dean NM; Levin AA
J Pharmacol Exp Ther; 2001 Feb; 296(2):388-95. PubMed ID: 11160622
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes.
Yu RZ; Geary RS; Leeds JM; Watanabe T; Fitchett JR; Matson JE; Mehta R; Hardee GR; Templin MV; Huang K; Newman MS; Quinn Y; Uster P; Zhu G; Working PK; Horner M; Nelson J; Levin AA
Pharm Res; 1999 Aug; 16(8):1309-15. PubMed ID: 10468036
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Metabolite Profiles of an
Li XQ; Elebring M; Dahlén A; Weidolf L
Drug Metab Dispos; 2023 Oct; 51(10):1350-1361. PubMed ID: 37429729
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
14. Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of GalNAc3-Conjugated and Unconjugated-Antisense Oligonucleotides.
Nanavati C; McMullen G; Yu R; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2021 Aug; 31(4):298-308. PubMed ID: 33891483
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.
Yu RZ; Geary RS; Leeds JM; Watanabe T; Moore M; Fitchett J; Matson J; Burckin T; Templin MV; Levin AA
J Pharm Sci; 2001 Feb; 90(2):182-93. PubMed ID: 11169535
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.
Sewell KL; Geary RS; Baker BF; Glover JM; Mant TG; Yu RZ; Tami JA; Dorr FA
J Pharmacol Exp Ther; 2002 Dec; 303(3):1334-43. PubMed ID: 12438559
[TBL] [Abstract][Full Text] [Related]
18. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.
Yu RZ; Kim TW; Hong A; Watanabe TA; Gaus HJ; Geary RS
Drug Metab Dispos; 2007 Mar; 35(3):460-8. PubMed ID: 17172312
[TBL] [Abstract][Full Text] [Related]
19. Integrated Assessment of Phase 2 Data on GalNAc
Baker BF; Xia S; Partridge W; Kwoh TJ; Tsimikas S; Bhanot S; Geary RS
Nucleic Acid Ther; 2023 Jan; 33(1):72-80. PubMed ID: 36454263
[TBL] [Abstract][Full Text] [Related]
20. Identification of GalNAc-Conjugated Antisense Oligonucleotide Metabolites Using an Untargeted and Generic Approach Based on High Resolution Mass Spectrometry.
Husser C; Brink A; Zell M; Müller MB; Koller E; Schadt S
Anal Chem; 2017 Jun; 89(12):6821-6826. PubMed ID: 28520401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
